EP1492498A2 - Hfa-suspensionsformulierungen eines anhydrats - Google Patents

Hfa-suspensionsformulierungen eines anhydrats

Info

Publication number
EP1492498A2
EP1492498A2 EP03717219A EP03717219A EP1492498A2 EP 1492498 A2 EP1492498 A2 EP 1492498A2 EP 03717219 A EP03717219 A EP 03717219A EP 03717219 A EP03717219 A EP 03717219A EP 1492498 A2 EP1492498 A2 EP 1492498A2
Authority
EP
European Patent Office
Prior art keywords
hfa
acid
contain
suspensions
tiotropium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03717219A
Other languages
German (de)
English (en)
French (fr)
Inventor
Christel Schmelzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Publication of EP1492498A2 publication Critical patent/EP1492498A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics

Definitions

  • the invention relates to propellant gas preparations for metered dose aerosols with suspension formulations of the crystalline anhydrate of (1c., 2ß, 4ß, 5 ⁇ , 7ß) -7- [(hydroxydi-2-thienylacetyl) oxy] -9,9-dimethyl-3-oxa-9- azoniatricyclo [3.3.1.0 2 ' 4 ] nonane bromide.
  • Patent application EP 418 716 A1 known and has the following chemical
  • Tiotropium bromide is preferably administered by inhalation.
  • the object of the present invention is to provide HFA metered dose aerosols containing tiotropium bromide as the only active substance in suspended form.
  • the present invention relates to suspensions of this crystalline tiotropium bromide anhydrate in the propellant gases HFA 227 and / or HFA 134a, optionally in a mixture with one or more further propellant gases, preferably selected from the group consisting of propane, butane, pentane, dimethyl ether, CHCIF 2 , CH 2 F 2) CF 3 CH 3 , isobutane, isopentane and neopentane.
  • crystalline tiotropium bromide anhydrate in the context of the present invention, this should be regarded as a reference to the anhydrous, crystalline modification of the tiotropium bromide which can be obtained by drying the crystalline tiotropium bromide monohydrate.
  • this crystal modification is optionally also referred to as crystalline tiotropium bromide in anhydrous form.
  • suspensions are preferred according to the invention which contain only HFA 227, a mixture of HFA 227 and HFA 134a or only HFA 134a as the propellant gas. If a mixture of the propellant gases HFA 227 and HFA 134a is used in the suspension formulations according to the invention, the weight ratios in which these two propellant gas components can be used are freely variable.
  • one or more further propellants are selected in the suspension formulations according to the invention, selected from the group consisting of propane, butane, pentane, dimethyl ether, CHCIF 2 , CH 2 F 2 , CF 3 CH 3 , isobutane, If isopentane and neopentane are used, the proportion of this further propellant gas component is preferably below 50%, preferably below 40%, particularly preferably below 30%.
  • the suspensions according to the invention preferably contain between 0.001 to 0.8% tiotropium. Suspensions which contain 0.08 to 0.5%, particularly preferably 0.2 to 0.4% tiotropium are preferred according to the invention.
  • Tiotropium is the free ammonium cation.
  • the propellant gas suspensions according to the invention are characterized in that they contain tiotropium in the form of the crystalline tiotropium bromide anhydrate which is outstandingly suitable for this application. Accordingly, the present invention preferably relates to suspensions containing between 0.0012 and 96% crystalline tiotropium bromide anhydrate. Of particular interest according to the invention are suspensions which contain 0.096 to 0.6%, particularly preferably 0.24 to 0.48%, crystalline tiotropium bromide anhydrate.
  • the percentages given in the context of the present invention are always mass percentages. If mass fractions for tiotropium are expressed in mass percentages, the corresponding values for the crystalline tiotropium bromide anhydrate preferably used in the context of the present invention can be obtained by multiplying by the conversion factor 1, 2036.
  • suspension formulation may also be used instead of the term suspension. Both terms are to be regarded as equivalent within the scope of the present invention.
  • the inhalation aerosols or suspension formulations containing propellant gas according to the invention may also contain further constituents such as surface-active agents (surfactants, surfactants), adjuvants, antioxidants or flavoring agents.
  • surface-active agents surfactants, surfactants, adjuvants, antioxidants or flavoring agents.
  • the surface-active agents (surfactants, surfactants) optionally contained in the suspensions according to the invention are preferably selected from the group consisting of polysorbate 20, polysorbate 80, Myvacet 9-45, Myvacet 9-08, isopropyl myristate, oleic acid, propylene glycol, polyethylene glycol, Brij, ethyl oleate, Glyceryl trioleate glyceryl monolaurate, glyceryl monooleate, glyceryl monosterate, glyceryl monoricinoleate, cetyl alcohol, steryl alcohol, cetyl pyridinum chloride, block polymers, natural oil, ethanol and isopropanol.
  • polysorbate 20, polysorbate 80, Myvacet 9-45, Myvacet 9-08 or isopropyl myristate are preferably used.
  • Myvacet 9-45 or isopropyl myristate are particularly preferably used.
  • surface-active agents are present in the suspensions according to the invention, these are preferably used in a proportion of 0.0005-1%, particularly preferably 0.005-0.5%.
  • the adjuvants optionally contained in the suspensions according to the invention are preferably selected from the group consisting of alanine, albumin, ascorbic acid, aspartame, betaine, cysteine, phosphoric acid, nitric acid, hydrochloric acid, sulfuric acid and citric acid.
  • Ascorbic acid, phosphoric acid, hydrochloric acid or citric acid are particularly preferably used, particularly preferably hydrochloric acid or citric acid. If adjuvants are present in the suspensions according to the invention, these are preferably used in a proportion of 0.0001-1.0%, preferably 0.0005-0.1%, particularly preferably 0.001-0.01%, a proportion of 0.001 -0.005% according to the invention is of particular importance.
  • the antioxidants optionally present in the suspensions according to the invention are preferably selected from the group consisting of ascorbic acid, citric acid, sodium edetate, editic acid tocopherols, butylated hydroxytoluene, butylated hydroxyanisole and ascorbyl palmitate, with tocopherols, butylated hydroxytoluene, butylated hydroxyanisole or ascorbyl palmitate being used with preference.
  • the flavoring agents optionally contained in the suspensions according to the invention are preferably selected from the group consisting of peppermint, sacharin, dentomint, aspartame and essential oils (for example cinnamon, anise, menthol, camphor), with peppermint or Dentomint® being particularly preferred.
  • Process obtained in finely divided form.
  • the active substance After micronization, the active substance preferably has an average particle size of 0.5 to 10 ⁇ m, preferably 1 to 6 ⁇ m, particularly preferably 1.5 to 5 ⁇ m. At least 50%, preferably at least 60%, particularly preferably at least 70% of the active ingredient particles preferably have a particle size which lies within the size ranges mentioned above. Particularly preferred at least 80%, most preferably at least 90% of the active ingredient particles with their particle size are in the ranges mentioned above.
  • suspensions can also be prepared which, in addition to the propellant gases mentioned, only contain the active ingredient and no further additives. Accordingly, a further aspect of the present invention is aimed at suspensions which only contain the active ingredient without further additives.
  • the suspensions according to the invention can be prepared by methods known in the art.
  • the constituents of the formulation are mixed with the propellant gas (s) (if appropriate at low temperatures) and filled into suitable containers.
  • pMDIs pressurized metered dose inhalers
  • a further aspect of the present invention relates to medicaments in the form of suspensions as described above in connection with one or more inhalers suitable for the administration of these suspensions.
  • the present invention relates to inhalers, characterized in that they contain suspensions containing propellant gas according to the invention described above.
  • the present invention further relates to containers (cartridges) which can be used with a suitable valve in a suitable inhaler and which contain one of the above-mentioned suspensions containing propellant gas according to the invention. Suitable containers (cartridges) and methods for filling these cartridges with the suspensions containing propellant gas according to the invention are known from the prior art.
  • the present invention further relates to the use of the suspensions according to the invention for the manufacture of a medicament which can be administered by inhalation or nasal administration, preferably for the manufacture of a medicament for the inhalative or nasal treatment of diseases in which anticholinergics can have a therapeutic benefit.
  • the present invention particularly preferably further relates to the use of the suspensions according to the invention for producing a medicament for inhalation treatment of respiratory diseases, preferably asthma or COPD.
  • the tiotropium bromide obtainable according to EP 418 716 A1 can be used to prepare the crystalline tiotropium bromide monohydrate. This is then implemented as described below.
  • the crystalline tiotropium bromide monohydrate obtainable according to the procedure described above was subjected to an investigation by means of DSC (differential scanning calorimetry).
  • the DSC diagram has two characteristic signals. The first, relatively broad, endothermic signal between 50-120 ° C is due to the dehydration of the tiotropium bomide monohydrate to the anhydrous form. The second, relatively sharp, endothermic maximum at 230 ⁇ 5 ° C is attributable to the melting of the substance.
  • This data was obtained using a Mettler DSC 821 and evaluated using the Mettler software package STAR. The data were collected at a heating rate of 10 K / min.
  • the crystalline tiotropium bromide monohydrate was characterized by means of IR spectroscopy. The data were collected using a Nicolet FTIR spectrometer and evaluated with the Nicolet software package OMNIC, version 3.1. The measurement was carried out with 2.5 ⁇ mol tiotropium bromide monohydrate in 300 mg KBr.
  • AFC7R-4 circular diffractometer Rasterku
  • the structure solution and refinement of the crystal structure was carried out using direct methods (program SHELXS86) and FMLQ refinement (program TeXsan).
  • the crystalline tiotropium bromide monohydrate obtained as described above is dried by careful drying at 80-100 ° C. under reduced pressure, preferably in a high vacuum for a period of at least 30
  • the anhydrous form can also be produced by storing it over dried silica gel at room temperature for a period of at least 24 hours.
  • the crystalline tiotropium bromide anhydrate obtainable by the above process is micronized according to processes known per se in the prior art with the exclusion of moisture in order to provide the active ingredient in the form of the average particle size which corresponds to the specifications according to the invention.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
EP03717219A 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats Withdrawn EP1492498A2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10214264 2002-03-28
DE10214264A DE10214264A1 (de) 2002-03-28 2002-03-28 HFA-Suspensionsformulierungen eines Anhydrats
PCT/EP2003/002899 WO2003082244A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats

Publications (1)

Publication Number Publication Date
EP1492498A2 true EP1492498A2 (de) 2005-01-05

Family

ID=28050990

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03717219A Withdrawn EP1492498A2 (de) 2002-03-28 2003-03-20 Hfa-suspensionsformulierungen eines anhydrats

Country Status (21)

Country Link
EP (1) EP1492498A2 (ru)
JP (1) JP5147158B2 (ru)
KR (1) KR101005717B1 (ru)
CN (1) CN1642525A (ru)
AU (1) AU2003221509B2 (ru)
BR (1) BR0308709A (ru)
CA (1) CA2479638C (ru)
DE (1) DE10214264A1 (ru)
EA (1) EA008610B1 (ru)
EC (1) ECSP045322A (ru)
HR (1) HRP20040890A2 (ru)
IL (1) IL163696A0 (ru)
ME (1) ME00246B (ru)
MX (1) MXPA04009338A (ru)
NO (1) NO20044004L (ru)
NZ (1) NZ536030A (ru)
PL (1) PL371295A1 (ru)
RS (1) RS52481B (ru)
UA (1) UA79776C2 (ru)
WO (1) WO2003082244A2 (ru)
ZA (1) ZA200405637B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2606549A1 (en) * 2005-05-02 2006-11-09 Boehringer Ingelheim International Gmbh Crystalline forms of tiotropium bromide
KR20080007656A (ko) * 2005-05-02 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 티오트로피움 브로마이드의 신규한 결정질 형태
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
DK2435024T3 (en) * 2009-05-29 2016-10-24 Pearl Therapeutics Inc Compositions for the respiratory delivery of active agents and related methods and systems
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
WO2014144894A1 (en) 2013-03-15 2014-09-18 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
MX2019003097A (es) * 2016-09-19 2019-09-13 Mexichem Fluor Sa De Cv Composicion farmaceutica.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931041C2 (de) * 1989-09-16 2000-04-06 Boehringer Ingelheim Kg Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US6475467B1 (en) * 1998-08-04 2002-11-05 Jago Research Ag Medicinal aerosol formulations
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
GB0009606D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Therapeutic combinations
GB0009592D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory combinations
EP1341538B1 (de) * 2000-10-31 2009-12-23 Boehringer Ingelheim Pharma GmbH & Co.KG Arzneimittelkompositionen aus tiotropiumsalzen und epinastin zur therapie von atemswegserkrankungen
DE10113366A1 (de) * 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
DE10111058A1 (de) * 2001-03-08 2002-09-12 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und NK¶1¶-Rezeptor-Antagonisten

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03082244A2 *

Also Published As

Publication number Publication date
KR20040098022A (ko) 2004-11-18
PL371295A1 (en) 2005-06-13
EA008610B1 (ru) 2007-06-29
KR101005717B1 (ko) 2011-01-05
DE10214264A1 (de) 2003-10-16
CN1642525A (zh) 2005-07-20
WO2003082244A3 (de) 2004-02-05
JP5147158B2 (ja) 2013-02-20
EA200401159A1 (ru) 2005-04-28
ECSP045322A (es) 2005-01-28
CA2479638A1 (en) 2003-10-09
BR0308709A (pt) 2005-01-04
CA2479638C (en) 2011-01-04
WO2003082244A2 (de) 2003-10-09
YU86004A (sh) 2006-08-17
AU2003221509B2 (en) 2008-01-24
JP2005527550A (ja) 2005-09-15
NZ536030A (en) 2006-07-28
UA79776C2 (en) 2007-07-25
HRP20040890A2 (en) 2005-06-30
ME00246B (me) 2011-05-10
IL163696A0 (en) 2005-12-18
NO20044004L (no) 2004-10-05
MXPA04009338A (es) 2005-01-25
RS52481B (en) 2013-02-28
MEP47308A (en) 2011-02-10
AU2003221509A1 (en) 2003-10-13
ZA200405637B (en) 2005-07-27

Similar Documents

Publication Publication Date Title
EP1809243B1 (de) Aerosolsuspensionsformulierungen mit tg 227 ea als treibmittel
EP1326862B1 (de) Kristallines monohydrat von tiotropiumbromid, verfahren zu dessen herstellung und dessen verwendung zur herstellung eines arzneimittels
WO1997005136A1 (de) Ein enantiomer von ipratropiumbromid mit verlängerter wirkungsdauer
EP1682542B1 (de) Neues kristallines anhydrat mit anticholinerger wirksamkeit
WO1993018746A1 (de) Druckgaspackungen unter verwendung von polyoxyethylen-glyceryl-oleaten
US20080044361A1 (en) HFA Suspension Formulations Containing an Anticholinergic
EP1695701B1 (de) HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum
EP2083007A1 (de) Tiotropiumsalze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittelformulierungen
WO2003082244A2 (de) Hfa-suspensionsformulierungen eines anhydrats
EP2067779A1 (de) Tiotropiumsalze, Verfahren zu deren Herstellung und Arzneimittelformulierungen diese enthaltend
US7244415B2 (en) HFA suspension formulations of an anhydrate
DE102004032322A1 (de) Aerosolsuspensionsformulierungen mit TG 227 ea als Teibmittel
DE10209243A1 (de) Neue Arzneimittelkombination zur Inhalation
DE10145438A1 (de) Neue Arzneimittel zur Inhalation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041028

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20161001